U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07872033) titled 'Aleniglipron Hepatic Impairment Study' on Oct. 07.
Brief Summary: The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: Aleniglipron
administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Disclaimer: Curated by HT Syndication....